Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial

Author:

Komócsi András1ORCID,Merkely Béla2ORCID,Hadamitzky Martin3ORCID,Massberg Steffen4ORCID,Rizas Konstantinos D4,Hein-Rothweiler Ralph4,Gross Lisa4,Trenk Dietmar56ORCID,Sibbing Dirk4ORCID,Aradi Dániel27ORCID

Affiliation:

1. Heart Centre, Medical School, University of Pécs , Pécs , Hungary

2. Heart and Vascular Centre, Semmelweis University , Budapest , Hungary

3. German Heart Center of Munich , Munich , Germany

4. Ludwig-Maximilians University , Munich , Germany

5. Department of Cardiology and Angiology–Clinical Pharmacology, Medical Center–University of Freiburg , Freiburg , Germany

6. Faculty of Medicine, University of Freiburg , Germany

7. Balatonfured State Cardiology Hospital , Balatonfured , Hungary

Abstract

Abstract Aims Clinical guidelines recommend de-escalation antiplatelet strategies to reduce bleeding risk in acute coronary syndrome (ACS) patients, albeit with a weak recommendation. This substudy of the TROPICAL-ACS trial aimed to determine the impact of body mass on the efficacy of a platelet function testing-guided de-escalation regimen in ACS patients after percutaneous coronary intervention. Methods and results Patients were randomized to prasugrel (control group) or a platelet function testing-guided regimen with clopidogrel or prasugrel defined after 1-week clopidogrel. The primary endpoint was the net clinical benefit [cardiovascular death, myocardial infarction, stroke, or Bleeding Academic Research Consortium (BARC) 2–5 bleeding] for 12 months. Overweight was defined as a body mass index >25 kg/m2. Patients without overweight showed a significant net clinical benefit from the de-escalation strategy, while in overweight cases de-escalation was comparable to prasugrel treatment [hazard ratio (HR): 0.52; 95% confidence interval (CI): 0.31–0.88; P = 0.013 and HR: 0.95; 95% CI: 0.69–1.31, P = 0.717, P-non-inferiority = 0.03, respectively, P-interaction = 0.053]. The benefit of de-escalation in terms of the risk of bleeding or of the ischaemic events did not reach statistical significance. Bleeding events with de-escalation were less frequent in non-overweight patients but comparable in overweight patients (HR: 0.55; 95% CI: 0.30–1.03; P = 0.057 and HR: 0.95; 95% CI: 0.64–1.41, respectively, P-interaction = 0.147). Non-overweight patients had lower ischaemic event rates with de-escalation, while overweight cases had slightly less (HR: 0.47; 95% CI: 0.18–1.25; P = 0.128 and HR: 0.89; 95% CI: 0.53–1.50, respectively, P-interaction = 0.261). Conclusion The strategy of guided dual antiplatelet therapy de-escalation was associated with a significant net clinical benefit in non-overweight patients, while the two strategies were equivalent in overweight patients.

Funder

Roche Diagnostics

Daiichi Sankyo Company

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3